Medicare Enrolled
Dr. Ashkan Abbey, M.D.
Ophthalmology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Abbey from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abbey?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Abbey
Dr. Ashkan Abbey is an ophthalmology specialist in Dallas, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Abbey performed 129,195 Medicare services across 6,075 unique beneficiaries.
Between the years covered by Open Payments, Dr. Abbey received a total of $507,093 from 42 pharmaceutical and/or device companies across 755 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Abbey is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 1% volume in TX
$507,093 industry payments
Medicare Practice Summary
Medicare Utilization ↗129,195
Medicare services
Top 1% in TX for ophthalmology
6,075
Unique beneficiaries
$50
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,600 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
108,194 | $29 | $83 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
4,397 | $31 | $100 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
3,862 | $90 | $200 |
| Ranibizumab-eqrn injection, 0.1 mg An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose. |
3,004 | $219 | $504 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
2,655 | $99 | $1,212 |
| Triamcinolone acetonide injection, 1 mg An injection of triamcinolone acetonide, a corticosteroid medication, administered in a 1 mg dose. |
1,956 | $38 | $115 |
| Aflibercept eye injection (Eylea) | 1,299 | $675 | $2,245 |
| Dexamethasone intravitreal implant injection An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye. |
826 | $155 | $425 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
489 | $47 | $130 |
| Fluocinolone acetonide intravitreal implant An implant containing fluocinolone acetonide is placed inside the eye to deliver medication directly to the vitreous. |
418 | $385 | $974 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
353 | $118 | $280 |
| Pegcetacoplan intravitreal injection, 1 mg An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram. |
330 | $120 | $333 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
220 | $18 | $105 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
180 | $106 | $285 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
164 | $29 | $165 |
| Unclassified biologic A biologic product that does not have a specific HCPCS code assigned. |
155 | $1,250 | $2,839 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
98 | $37 | $305 |
| Additional 30 minutes of principal care management This service covers each additional 30 minutes of clinical staff time directed by a healthcare professional for managing a single high-risk disease, billed per calendar month. |
98 | $37 | $100 |
| Vitreous removal between lens and retina This procedure involves the removal of the vitreous fluid located between the lens and the retina of the eye. |
87 | $553 | $4,000 |
| Corneal topography and eye depth measurement This procedure measures the curvature and depth of the cornea, the clear front surface of the eye. |
82 | $17 | $120 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
60 | $2,033 | $6,117 |
| Prosthetic lens exchange Surgical removal of an existing artificial lens and replacement with a new one. |
51 | $636 | $1,500 |
| Retinal membrane and internal limiting membrane removal A surgical procedure to remove a membrane from the retina along with the internal limiting membrane of the retina. |
38 | $909 | $5,700 |
| Compounded drug, not otherwise classified A medication prepared specifically for an individual patient by a pharmacist or physician, tailored to meet unique needs that cannot be fulfilled by commercially available products. |
32 | $77 | $203 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
26 | $52 | $150 |
| Injection into suprachoroidal space of eye A procedure involving the injection of medication into the space located above the choroid membrane of the eye. |
25 | $90 | $900 |
| Complex detached retina repair with eye fluid drainage A surgical procedure to repair a detached retina and drain fluid located between the lens and the retina. |
24 | $1,027 | $6,500 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
24 | $63 | $200 |
| Laser vitreolysis A laser procedure used to destroy fluid in the vitreous of the eye, located between the lens and the retina. |
22 | $730 | $4,800 |
| Retinal detachment repair with fluid drainage A surgical procedure to reattach a detached retina by draining excess fluid from the space between the lens and the retina. |
15 | $940 | $6,000 |
| Laser removal of recurring cataract A laser procedure to remove a recurring cataract within the lens capsule. |
11 | $252 | $1,500 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$507,093
Total received (2018-2024)
Avg $72,442/year across 7 years
Top 1% in TX for ophthalmology
42
Companies
755
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$366,061 (72.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$136,896 (27.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,136 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$86,653
2023
$141,032
2022
$92,609
2021
$50,631
2020
$39,460
2019
$65,541
2018
$31,167
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$102,007
Genentech USA, Inc.
$51,861
Astellas Pharma US Inc
$45,711
Apellis Pharmaceuticals, Inc.
$44,829
Novartis Pharmaceuticals Corporation
$41,809
Alimera Sciences, Inc.
$40,882
F. Hoffmann-La Roche AG
$22,422
Allergan Inc.
$21,483
EyePoint Pharmaceuticals US, Inc.
$19,429
Biogen, Inc.
$17,915
Allergan, Inc.
$17,249
ABBVIE INC.
$17,031
Novartis Pharma AG
$9,225
Alcon Research LLC
$7,196
Spark Therapeutics, Inc.
$7,083
Hoffmann-La Roche Limited
$7,083
Coherus Biosciences Inc.
$6,935
Alcon Vision LLC
$5,593
Bausch & Lomb Americas Inc.
$5,276
Regeneron Pharmaceuticals, Inc.
$4,398
Genentech, Inc.
$2,178
ThromboGenics, Inc.
$2,057
NOVARTIS PHARMACEUTICALS CORPORATION
$2,050
Ocular Therapeutix, Inc.
$2,016
Beaver-Visitec International, Inc.
$1,550
AbbVie Inc.
$415
NotalVision
$312
Sandoz Inc.
$275
Harrow Eye, LLC
$139
Carl Zeiss Meditec USA, Inc.
$109
Bausch & Lomb, a division of Bausch Health US, LLC
$84
Amgen Inc.
$80
Carl Zeiss Meditec, Inc.
$70
Kala Pharmaceuticals, Inc.
$64
Iridex Corporation
$58
Horizon Therapeutics plc
$53
Alcon Laboratories Inc
$52
Halozyme Inc
$33
Takeda Pharmaceuticals U.S.A., Inc.
$27
VYERA PHARMACEUTICALS, LLC
$23
Vyera Pharmaceuticals, LLC
$20
AbbVie, Inc.
$16
Top 3 companies account for 39.4% of total payments
Associated products mentioned in payments ›
ACTIVEFOCUS · ALREX · BEOVU · BROLUCIZUMAB · BYOOVIZ · Cimerli · Constellation · DEXYCU · DUREZOL · Daraprim · Daraprim Tablet 25mg · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYP-1901 · ForeseeHome · HYLENEX RECOMBINANT · Humira · IHEEZO · ILUVIEN · INVELTYS · Iluvien · Izervay · Jetrea · LOTEMAX GEL · LUMERA · LUXTURNA · LenSx · Lucentis · Luxor · OZURDEX · PAVBLU · RETISERT · ReSure Sealant · SUSVIMO · Simbrinza · Susvimo · Syfovre · TEPEZZA · Udenyca · VABYSMO · VISUDYNE · VPRIV · Vabysmo · XIPERE · YUTIQ · enVista MX60 IOL · rhopressa
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (72%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for ophthalmology in TX.
Equivalent to $392 per 100 Medicare services performed
Geographic Context
Ophthalmologists within 10 mi
285
Per 100K population
10.9
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Abbey is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with speaking/promotional industry engagement in the top 1% of TX peers, with 17 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Abbey experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Abbey performed 108,194 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abbey receive payments from pharmaceutical companies?
Yes. Dr. Abbey received a total of $507,093 from 42 companies across 755 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abbey's costs compare to other ophthalmologists in Dallas?
Dr. Abbey's average Medicare payment per service is $50. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abbey) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Ophthalmologists in Dallas
Browse ophthalmologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Ophthalmologists in TX
Ophthalmologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Ophthalmologists in TX
Which TX ophthalmologists receive the most from drug and device companies.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology